A coalition of 45 states and territories has asked a federal court to approve settlements with three generic-drug companies, Ascend Laboratories, Mayne Pharma and Citron Pharma. The settlements are small, and one of them involves no money at all. They matter because they are the latest step in a long price-fixing case that heads to its first trial in February 2027 in Hartford, Connecticut.
What the states announced
Pennsylvania Attorney General Dave Sunday’s office announced the filing on Oct. 8, 2026, in a release from his Antitrust Section. Ascend will pay $400,000 and Mayne will pay $650,000, both to the states. The release says each company also agreed to reforms meant to protect fair competition and antitrust compliance.
The states say the companies took part in a widespread, long-running conspiracy to raise prices and reduce consumer options for generic prescription drugs. Those are the states’ allegations, and the settling companies are not described in the release as admitting them. “By limiting market competition while inflating prices, Pennsylvanians had no recourse,” Sunday said.
What the court filing shows
The states’ memorandum to the court, dated Oct. 8, was filed in the U.S. District Court for the District of Connecticut. It asks for preliminary approval, which is an early finding that the deals look fair, reasonable and adequate. It does not ask for final approval yet.
The filing puts Citron’s relief at zero dollars. It says Citron “has ceased doing business” and agreed only to injunctive terms, meaning limits on its conduct. It also reports that the states estimate that any overcharges tied to Mayne’s conduct are minimal.
The question for people who bought generic drugs is whether any of this ends up in their pockets. For now, the answer is that a small pool is being set aside for consumers, but nothing can be paid until the court signs off. The filing says the attorneys general “will only distribute Restitution Account funds pursuant to a Court order.”
About $465,000 is set aside for consumers across the Ascend and Mayne deals, and nothing moves until the court approves it and a notice goes out. The Settlement & Refund Recovery System includes the four-date rule for reading a settlement notice, so the dates that matter are clear when the notice arrives.
Get the four-date rule for settlement notices in the Settlement & Refund Recovery System →
Where the money would go
The filing splits each payment 70/30. Thirty percent goes into a costs account for notice, administration, litigation costs and attorney fees: $191,176.50 from Mayne and $117,647.10 from Ascend. Seventy percent goes into a restitution account: $458,823.50 from Mayne and $282,352.90 from Ascend.
Consumers would draw from that restitution account. The filing sets aside consumer restitution funds of $288,004.42 from Mayne and $177,233.78 from Ascend, about 44 percent of the settlement funds, to be paid under a distribution plan the court preliminarily approved on Sept. 8, 2026. State agencies would get about 24 percent, and a small share, $12,745 from Mayne and $7,843 from Ascend, is earmarked for eligible corporate entities, with distribution put off.
If the court agrees, notice would begin within seven days of preliminary approval. People would then have 77 days to opt out or object. The filing also asks the court to name Rust Consulting as notice and claims administrator and to pause the litigation against the settling companies until final approval is decided.
A claims process already open
A separate claims process is open for earlier settlements in the same litigation. Connecticut Attorney General William Tong’s office said on Sept. 22 that people who bought a listed generic drug between May 2009 and December 2019 may be eligible for compensation, and the release points to the claim site, AGGenericDrugs.com. It covers settlements with Glenmark, Lannett, Bausch, Apotex, Heritage and Heritage’s parent company, Emcure, totaling about $96.5 million. The release gave no claim deadline.
“I am urging every Connecticut resident to check their medicine cabinets and records and apply for compensation,” Tong said. The Ascend and Mayne settlements are not part of that claims process yet.
The larger case
Sunday’s office says the states previously settled with Sandoz, Glenmark, Lannett, Bausch, Apotex and Heritage, and with Heritage’s parent company, Emcure, for a total of $496.5 million. Next to that figure, the Ascend and Mayne deals are modest. The states are preparing for the first trial, set for February 2027 in Hartford. The release does not give a day in February.
Tracking these settlements toward a claim
For anyone who bought generic prescriptions during the years at issue, the free first step is the claim site for the earlier settlements, along with the toll-free number and email address Connecticut’s office posted: 1-866-290-0182 and [email protected]. Because the window runs from May 2009 to December 2019, old pharmacy receipts, insurance statements and pill-bottle labels are worth finding.
For the Ascend and Mayne deals, the next signals are the court’s ruling on preliminary approval and the notice that follows it. That notice will carry the opt-out and objection deadline and the details of how to claim. Until it arrives, there is nothing to file.
The attorneys general’s own pages remain the best place to confirm each date, since the court has not yet ruled on either settlement.
A notice deadline will follow the court’s approval
When the court acts on the Ascend and Mayne deals, a 77-day clock to opt out or object is expected to start, and a missed date can mean a lost say. The Settlement & Refund Recovery System has a claim log and payment tracker for keeping each settlement’s dates and payments in one place.
Log each generic-drug settlement date in the claim log and payment tracker →
This article was produced with AI assistance and edited for accuracy against the sources linked above.
